Futura Medical is developing a portfolio of innovative products for two large markets, sexual health and pain.

MED2005, our lead product, is a topical glyceryl trinitrate (GTN) gel which has the potential to be a highly differentiated therapy, especially for mild to moderate ED.

Our product pipeline

Lead products

Concept Development Commercialisation
MED2005        
Description: Topical gel for erectile dysfunction DermaSys logo
Status: First Phase 3 study underway with headline data by end of 2019. Out-licensing discussions ongoing

TPR100        
Description: Topical diclofenac pain relief gel DermaSys logo
Status: Regulatory dossier submitted in the UK. UK licence partner addressing queries with support from Futura. Licensing discussions for further territories ongoing. 

Other products

Concept Development Commercialisation
CBD100        
Description: Topical Cannabidiol formulation DermaSys logo
Status: Joint venture collaboration. Early development stage to explore a number of disease states including pain relief.

CSD500        
Description: Condom containing an erectogenic gel  
Status: Approved in the EU, 24 month shelf life

TIB200        
Description: Topical ibuprofen pain relief gel DermaSys logo
Status: Out-licencing discussions ongoing